By Dr. Charles Kamen MD | LiveWell21 Regenerative Medicine | Las Vegas, NV
Stem cell therapy is one of the most promising and one of the most overhyped areas of modern medicine. As a board-certified neurologist who has studied regenerative medicine extensively, I want to give you something rare in this space: an honest assessment of what stem cell therapy can do, what it cannot do, and how to separate legitimate science from marketing noise.
Stem cells are undifferentiated cells with two defining properties: they can self-renew (divide to produce more stem cells) and they can differentiate (become specialized cell types like muscle, bone, cartilage, or nerve cells). These properties make them fundamentally important in tissue repair and regeneration.
Not all stem cells are equal. Understanding the differences is essential for evaluating treatment options.
Mesenchymal Stem Cells (MSCs): These are the workhorses of current regenerative medicine. Found in bone marrow, adipose (fat) tissue, and umbilical cord tissue, MSCs can differentiate into bone, cartilage, muscle, and fat cells. Critically, they also release anti-inflammatory and regenerative signaling molecules called paracrine factors. Much of their therapeutic benefit may come from this signaling activity rather than direct tissue replacement.
Hematopoietic Stem Cells (HSCs): Found in bone marrow, these give rise to all blood cell types. HSC transplantation is well-established for blood cancers and certain immune disorders. This is the most proven stem cell therapy in medicine.
Embryonic Stem Cells (ESCs): These can become any cell type in the body (pluripotent). They are powerful but raise ethical questions and carry risks including tumor formation. They are not used in outpatient regenerative medicine clinics.
Induced Pluripotent Stem Cells (iPSCs): Adult cells reprogrammed to an embryonic-like state. A groundbreaking research tool but still largely in clinical trials.
Most regenerative medicine clinics, including LiveWell21, work with adult stem cells derived from your own body (autologous) or from donated umbilical cord tissue (allogeneic). The two most common sources are:
Some clinics also offer products derived from umbilical cord tissue, amniotic fluid, or placental tissue. I want to be direct about something: many of these products, while marketed as "stem cell" treatments, may contain few or no viable stem cells by the time they reach the patient. The processing and storage methods significantly affect cell viability.
I organize the evidence into three tiers because intellectual honesty demands it. Patients deserve to know how strong the scientific backing is for any treatment I recommend.
Hematopoietic stem cell transplantation for blood cancers (leukemia, lymphoma, myeloma) and certain immune disorders. This is a well-established medical procedure performed in hospital settings with decades of outcomes data. It is not what outpatient regenerative medicine clinics offer.
Knee osteoarthritis: Multiple randomized controlled trials have evaluated BMAC and adipose-derived stem cell injections for knee osteoarthritis. Results show meaningful pain reduction and functional improvement in many patients, particularly those with mild to moderate disease. However, the evidence has not yet demonstrated consistent cartilage regeneration on imaging. The benefits may be primarily anti-inflammatory and pain-modulating rather than structurally regenerative.
Rotator cuff repair augmentation: Several studies show improved healing rates when stem cell preparations are used alongside surgical repair. This is a surgical adjunct, not a standalone treatment.
Bone non-union: BMAC has shown benefit in helping fractures that have failed to heal through normal processes.
Neurological conditions: As a neurologist, I follow this research closely. Stem cell therapy for conditions like multiple sclerosis, Parkinson's disease, spinal cord injury, and stroke is in active clinical trial phases. Results are encouraging in some trials but far from established. I would not recommend stem cell therapy as a primary treatment for neurological disease outside of a clinical trial at this time.
Disc degeneration: Early-phase trials show some promise for intervertebral disc repair, but the evidence is not yet sufficient to recommend routine clinical use.
Erectile dysfunction, anti-aging, general wellness: The evidence for these applications is preliminary at best. Claims of broad-spectrum rejuvenation should be viewed with significant skepticism.
This section is as important as the one above. I include it because too many clinics omit it.
Any clinic that guarantees results or claims stem cells can cure a serious disease should raise red flags.
Las Vegas has numerous clinics offering stem cell therapy, and quality varies enormously. Here is what to look for:
At our Las Vegas clinic, we approach stem cell therapy with the same evidence-based rigor we apply to every treatment we offer.
Before any treatment, we conduct a thorough evaluation that includes:
For patients who are appropriate candidates, the procedure involves:
BMAC Protocol: Under local anesthesia, bone marrow is aspirated from the posterior iliac crest using a specialized needle. The aspirate is processed in a centrifuge to concentrate the stem cells and growth factors. The concentrate is then injected into the treatment area under imaging guidance. Total procedure time is approximately 60-90 minutes.
Adipose-Derived Protocol: A small amount of fat is harvested from the abdomen or flank using tumescent liposuction technique under local anesthesia. The tissue is processed to isolate the stromal vascular fraction containing stem cells. The preparation is then injected into the target area. Total procedure time is approximately 90-120 minutes.
Recovery varies by procedure and treatment area:
Patients should understand the regulatory context. The FDA regulates stem cell products under the framework of human cells, tissues, and cellular and tissue-based products (HCT/Ps). Products that are "minimally manipulated" and used for "homologous use" (treating the type of tissue they came from) have a different regulatory pathway than those involving significant processing or non-homologous use.
This means that some stem cell treatments available in clinical settings are operating within FDA guidelines, while others may exist in a regulatory gray area. At LiveWell21, we adhere strictly to FDA guidance and are transparent about the regulatory status of any treatment we offer.
Stem cell therapy is not covered by insurance for most regenerative medicine applications. Costs are higher than PRP therapy due to the more involved harvesting and processing procedures. We provide complete cost information during your consultation, and we encourage patients to weigh costs against the current evidence level for their specific condition.
I entered regenerative medicine because the science is genuinely promising. The ability to harness the body's own repair mechanisms represents a potential paradigm shift in how we treat degenerative conditions. At the same time, I am troubled by the gap between what some clinics promise and what the evidence supports.
My commitment to patients at LiveWell21 is straightforward: I will recommend stem cell therapy when the evidence supports it for your specific condition, and I will recommend against it when it does not. Your health decisions deserve that honesty.
Schedule a consultation with Dr. Charles Kamen MD at LiveWell21. We will review your condition, discuss the evidence honestly, and help you make an informed decision about your treatment options.
Book Your Consultation at LiveWell21
LiveWell21 provides regenerative medicine services to patients throughout Las Vegas, Henderson, Summerlin, North Las Vegas, and the greater Clark County area.